Nitto Denko Avecia Inc. Strengthens its Commitment to the Small Molecule and Radiochemistry Industries by Hiring Hamilton J. Lenox as Director of Business Development

Biotechnology manufacturer Nitto Denko Avecia, Inc., has hired expert Hamilton J. Lenox to focus on promoting its small molecule and radiochemistry units.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
I look forward to expanding our client base in my new role, and know our existing and future clients will continue to be impressed with Avecia’s commitment to quality in everything we do.

(PRWEB) December 19, 2013

Nitto Denko Avecia Inc., an industry leader in process development and commercial manufacturing, is proud to announce that it has hired Hamilton J. Lenox as its new Director of Business Development. Hamilton initially will focus on the small molecule and radiochemistry units of Avecia, and also will be handling marketing for the organization. Hamilton brings both a strong technical background and significant business development expertise to Avecia, including familiarity both with clients and the outsourcing markets in North America, Europe and Asia.

The hiring of Hamilton, who is well known in the small molecule industry, demonstrates Avecia’s continuing commitment to their small molecule and radiochemistry customers. Early in 2013 Avecia acquired the contract manufacturing business of Girindus America Inc., adding small molecule API manufacturing and radiochemistry capabilities while expanding Avecia’s best in class oligonucleotide offerings.

Hamilton says he is excited to join Nitto Denko Avecia, Inc., a company well-known for their excellent reputation and strong leadership. “I look forward to expanding our client base in my new role, and know our existing and future clients will continue to be impressed with Avecia’s commitment to quality in everything we do,” says Hamilton. He notes that the acquisition of Girindus America’s contract manufacturing business not only keeps Avecia positioned as the leader of the oligonucleotide manufacturing market, but also significantly expands their capabilities.

Additionally, small molecule services have complemented Avecia’s oligonucleotide business due to both units’ expertise in difficult conjugation chemistry, and Avecia now can produce any necessary small molecule linkers / conjugates in-house. The expertise of Avecia’s oligo team also has benefited the small molecule unit by providing additional expertise that clearly positions Avecia as a leader in developing and manufacturing small molecule nucleotide derivatives and analogs. There also is a strong synergy between the oligo and radiochemistry units, as this combination marks Avecia as one of the only radiochemistry facilities in the world with significant expertise in oligo synthesis.

About Nitto Denko Avecia, Inc.:
Nitto Denko Avecia, Inc., is a drug development and manufacturing services company with headquarters in Milford, MA, and is a part of Nitto Denko Corporation, Japan’s leading diversified materials manufacturer. Avecia is a recognized leader in the oligonucleotide therapeutic market, and with the acquisition of Girindus America’s contract manufacturing business in 2013 has added radiochemistry and small molecule API development and manufacturing to its portfolio of services. Avecia’s oligonucleotide facilities (in Milford, MA, and Cincinnati, OH) support DNA and RNA-based therapeutics throughout their lifecycle, and include such services as process and analytical development and pre-clinical production through large scale cGMP commercial manufacturing. To see what Avecia can do for your business, visit http://www.avecia.com.


Contact

Attachments